FIELD: bioengineering.
SUBSTANCE: antibodies are specifically linked with the domain S1 C4.4a, are cross-reactive in relation to C4.4a rodents, and are internalised after linking with the cells expressing C4.4a. The invention can be used for the medical treatment and diagnostics of abnormalities and states linked with the C4.4a overexpression.
EFFECT: invention ensures the method of producing of the said antibodies, the conjugate of the said antibody with a pharmaceutical.
18 cl, 7 dwg, 18 tbl, 15 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NEW CONJUGATES BINDING COMPOUND - ACTIVE COMPOUND (ADC) AND USE THEREOF | 2012 |
|
RU2610336C2 |
| IL-17 ANTAGONIST ANTIBODIES | 2005 |
|
RU2426741C2 |
| MONOCLONAL ANTIBODIES AGAINST HUMAN TIM-3 | 2019 |
|
RU2777336C1 |
| ANTI c-Met RECEPTOR PROTEIN ANTIBODIES | 2011 |
|
RU2608644C2 |
| ANTIBODIES TO CANINE PD-1 | 2014 |
|
RU2761663C2 |
| HUMANIZED ANTI-C5 ANTIBODIES AND THEIR APPLICATION | 2019 |
|
RU2792237C2 |
| ANTI-LIGAND 1 ANTIBODY OF PROGRAMMED CELL DEATH (PD-L1), ITS ANTIGEN-BINDING FRAGMENT AND THEIR MEDICAL APPLICATION | 2016 |
|
RU2727914C2 |
| HUMAN ANTI-CD38-ANTIBODIES AND THEIR APPLICATION | 2005 |
|
RU2402568C2 |
| ANTI-GM-CSF ANTIBODIES AND USING THEM | 2006 |
|
RU2447085C2 |
| ANTIBODIES FOR TREATMENT OF HEPATITIS B INFECTION AND RELATED DISEASES | 2018 |
|
RU2765878C2 |
